158 related articles for article (PubMed ID: 28890729)
1. Clinical application of a cancer genomic profiling assay to guide precision medicine decisions.
Eifert C; Pantazi A; Sun R; Xu J; Cingolani P; Heyer J; Russell M; Lvova M; Ring J; Tse JY; Lyle S; Protopopov A
Per Med; 2017 Jul; 14(4):309-325. PubMed ID: 28890729
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors.
Martínez-Fernández P; Pose P; Dolz-Gaitón R; García A; Trigo-Sánchez I; Rodríguez-Zarco E; Garcia-Ruiz M; Barba I; Izquierdo-García M; Valero-Garcia J; Ruiz C; Lázaro M; Carbonell P; Gargallo P; Méndez C; Ríos-Martín JJ; Palmeiro-Uriach A; Camarasa-Lillo N; Forteza-Vila J; Calabria I
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33947144
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
4. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.
Liang J; She Y; Zhu J; Wei L; Zhang L; Gao L; Wang Y; Xing J; Guo Y; Meng X; Li P
Int J Oncol; 2016 Nov; 49(5):2088-2104. PubMed ID: 27826616
[TBL] [Abstract][Full Text] [Related]
6. Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors.
Conroy JM; Pabla S; Glenn ST; Burgher B; Nesline M; Papanicolau-Sengos A; Andreas J; Giamo V; Lenzo FL; Hyland FCL; Omilian A; Bshara W; Qin M; He J; Puzanov I; Ernstoff MS; Gardner M; Galluzzi L; Morrison C
J Mol Diagn; 2018 Jan; 20(1):95-109. PubMed ID: 29061374
[TBL] [Abstract][Full Text] [Related]
7. Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay.
Pabla S; Andreas J; Lenzo FL; Burgher B; Hagen J; Giamo V; Nesline MK; Wang Y; Gardner M; Conroy JM; Papanicolau-Sengos A; Morrison C; Glenn ST
Oncotarget; 2019 Aug; 10(50):5181-5193. PubMed ID: 31497248
[TBL] [Abstract][Full Text] [Related]
8. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'.
De Falco V; Poliero L; Vitello PP; Ciardiello D; Vitale P; Zanaletti N; Giunta EF; Terminiello M; Caputo V; Carlino F; Di Liello R; Ventriglia A; Famiglietti V; Martinelli E; Morgillo F; Orditura M; De Vita F; Fasano M; Napolitano S; Martini G; Della Corte CM; Franco R; Altucci L; Ciardiello F; Troiani T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32234730
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
11. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
12. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
[TBL] [Abstract][Full Text] [Related]
13. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
14. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.
Shao D; Lin Y; Liu J; Wan L; Liu Z; Cheng S; Fei L; Deng R; Wang J; Chen X; Liu L; Gu X; Liang W; He P; Wang J; Ye M; He J
Sci Rep; 2016 Mar; 6():22338. PubMed ID: 26936516
[TBL] [Abstract][Full Text] [Related]
15. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
[TBL] [Abstract][Full Text] [Related]
16. Analytical validation and implementation of a pan cancer next-generation sequencing panel, CANSeq
Schilter KF; Smith BA; Nie Q; Stoll K; Felix JC; Jarzembowski JA; Reddi HV
Front Genet; 2023; 14():1067457. PubMed ID: 36845394
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
[TBL] [Abstract][Full Text] [Related]
18. A novel molecular diagnostics platform for somatic and germline precision oncology.
Cabanillas R; Diñeiro M; Castillo D; Pruneda PC; Penas C; Cifuentes GA; de Vicente Á; Durán NS; Álvarez R; Ordóñez GR; Cadiñanos J
Mol Genet Genomic Med; 2017 Jul; 5(4):336-359. PubMed ID: 28717660
[TBL] [Abstract][Full Text] [Related]
19. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
Gailey MP; Stence AA; Jensen CS; Ma D
Cancer Cytopathol; 2015 Jan; 123(1):30-9. PubMed ID: 25186473
[TBL] [Abstract][Full Text] [Related]
20. Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.
Lin DI; Huang RSP; Ladas I; Keller RB; Patel NR; Lakis S; Decker B; Janovitz T; Mata DA; Ross JS; Vergilio JA; Elvin JA; Herbst RS; Mack PC; Killian JK
Front Oncol; 2024; 14():1328512. PubMed ID: 38444675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
